

January 7, 2019

To whom it may concern:

Company Name TOHO HOLDINGS CO., LTD.  
 Corporate Representative Norio Hamada, Chairman of the Board and Representative Director, Chief Executive Officer (CEO)  
 (First Section of Tokyo Stock Exchange Securities Code:8129)  
 Contact: Makoto Kawamura, Director and General Manager, Public and Investor Relations Department  
 (TEL: 81-3-6838-2803)

### Notice Regarding the Transfer of Sales Right of 1 Ingredient / 1 Product of Generic Drug for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director, Chief Executive Officer (CEO): Norio Hamada) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, regarding transfer of pharmaceutical marketing approvals and sales rights from FUJIFILM Pharma Co., Ltd. (Headquarters: Tokyo; Representative Director and President: Susumu Tanahashi) notified on July 27, 2018, completed transfer of sales right for 1 ingredient/ 1 product on January 1 as below.

#### 1. Transfer of sales right on January 1.

Product whose sale right is transferred

Class	Product Name	Original Brand Name
Allergic Conjunctivitis Therapeutic Agent	Cromoglicate Ophthalmic Solution 2% "Kyorin"	Intal Ophthalmic Solution 2%